Investors purchased shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on weakness during trading hours on Friday. $93.31 million flowed into the stock on the tick-up and $55.86 million flowed out of the stock on the tick-down, for a money net flow of $37.45 million into the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 22nd highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($1.30) for the day and closed at $366.96
A number of equities research analysts recently issued reports on the stock. Citigroup restated a “neutral” rating and issued a $388.00 target price (up from $380.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, January 9th. Argus lowered their target price on shares of Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating for the company in a report on Thursday, December 28th. Royal Bank of Canada restated a “hold” rating and issued a $430.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, December 14th. Deutsche Bank assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 12th. They issued a “hold” rating and a $397.00 target price for the company. Finally, TheStreet downgraded shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, November 30th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $471.11.
The company has a market cap of $39,430.00, a P/E ratio of 33.33, a price-to-earnings-growth ratio of 1.41 and a beta of 1.52. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.13 earnings per share. equities research analysts predict that Regeneron Pharmaceuticals Inc will post 13.55 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Shell Asset Management Co. boosted its stake in shares of Regeneron Pharmaceuticals by 24.1% in the third quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock valued at $5,565,000 after purchasing an additional 2,999 shares during the period. Northpointe Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $2,089,000. Cubist Systematic Strategies LLC boosted its stake in shares of Regeneron Pharmaceuticals by 176.1% in the second quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 428 shares during the period. Griffin Asset Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $1,579,000. Finally, Prentiss Smith & Co. Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $416,000. Institutional investors and hedge funds own 66.63% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/01/14/traders-buy-shares-of-regeneron-pharmaceuticals-regn-on-weakness.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.